(19:59 GMT) Gain Therapeutics Price Target Maintained With a $5.00/Share by BTIG
DO Dow Jones Newswires Gain Therapeutics Is Maintained at Buy by BTIG 7/1/2026, 03:59 AM GMT+8 Dow Jones Newswires GA GANX (19:59 GMT) Gain Therapeutics Price Target Maintained With a $5.00/Share by BTIG Market News Dow Jones Newswires Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co. Stocktwits Why Is GANX Stock Rallying 22% After Hours? Dow Jones Newswires Gain Therapeutics Gets FDA Approval to Start Phase 2 Study of Parkinson's Drug Dow Jones Newswires Gain Therapeutics Gets FDA Approval to Start Phase 2 Study of Parkinson's Drug
